Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
June 7, 2023
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Exai Bio's core technology is founded on UCSF research done by Hani Goodarzi, PhD.